Cargando…

Prognostic value of PTEN in de novo diagnosed metastatic prostate cancer

The purpose of our study is to investigate the prognostic value of phosphatase and tensin homolog on chromosome 10 (PTEN) expression in patients with de novo metastatic castration naïve prostate cancer (mCNPC). A total of 205 patients with mCNPC at Fudan University Shanghai Cancer Center (Shanghai,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jun-Yu, Kong, Yun-Yi, Wang, Qi-Feng, Yang, Yun-Jie, Liu, Zheng, Lin, Nan, Ye, Ding-Wei, Dai, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788606/ https://www.ncbi.nlm.nih.gov/pubmed/34100390 http://dx.doi.org/10.4103/aja.aja_39_21

Ejemplares similares

Prognostic value of genomic mutations in metastatic prostate cancer()()
por: Zhu, Honghui, et al.
Publicado: (2023)

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer
por: Cuzick, J, et al.
Publicado: (2013)

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers
por: Rescigno, Pasquale, et al.
Publicado: (2018)

Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer
por: NOH, BYEONG-JOO, et al.
Publicado: (2016)

Development and validation of a novel risk model in newly diagnosed de novo bone metastatic prostate cancer (M1b): a retrospective study
por: Zhang, Yang, et al.
Publicado: (2023)

Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer
por: Ulaner, Gary A, et al.
Publicado: (2013)

Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
por: Chen, Yu, et al.
Publicado: (2015)

Prognostic Value of Local Treatment in Prostate Cancer Patients With Different Metastatic Sites: A Population Based Retrospective Study
por: Jin, Shengming, et al.
Publicado: (2020)

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

Prognostic value of bone scan index as an imaging biomarker in metastatic prostate cancer: a meta-analysis
por: Li, Dongyang, et al.
Publicado: (2017)

Differential prognostic factors in low‐ and high‐burden de novo metastatic hormone‐sensitive prostate cancer patients
por: Shiota, Masaki, et al.
Publicado: (2021)

High IL-23(+) cells infiltration correlates with worse clinical outcomes and abiraterone effectiveness in patients with prostate cancer
por: Liu, Zheng, et al.
Publicado: (2021)

The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer
por: Wang, Zhipeng, et al.
Publicado: (2023)

Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer
por: Chang, Kun, et al.
Publicado: (2015)

Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer
por: Barcenas, Carlos H., et al.
Publicado: (2021)

The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer
por: Turnham, Daniel J., et al.
Publicado: (2020)

The metastasis patterns and their prognostic features in patients with de novo metastatic breast cancer of different ages
por: Sun, Shujuan, et al.
Publicado: (2023)

Retraction to the prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer
por: Wang, Zhipeng, et al.
Publicado: (2023)

Source, co-occurrence, and prognostic value of PTEN mutations or loss in colorectal cancer
por: Serebriiskii, Ilya G., et al.
Publicado: (2023)

Maximal standard uptake values of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography compared with Epstein-Barr virus DNA as prognostic indicators in de novo metastatic nasopharyngeal carcinoma patients
por: Sun, Xue-Song, et al.
Publicado: (2019)

Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2020)

Prognostic Score for De Novo Metastatic Breast Cancer With Liver Metastasis and Its Predictive Value of Locoregional Treatment Benefit
por: Ji, Lei, et al.
Publicado: (2021)

Addition of chemoradiotherapy to palliative chemotherapy in de novo metastatic nasopharyngeal carcinoma: a real-world study
por: Zheng, Shuo-Han, et al.
Publicado: (2022)

Prognostic Value of an Immunohistochemical Signature in Patients With Bladder Cancer Undergoing Radical Cystectomy
por: Wu, Jie, et al.
Publicado: (2021)

Expression and significance of PTEN and Claudin-3 in prostate cancer
por: Ye, Xinglong, et al.
Publicado: (2019)

A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss
por: Myint, Zin W., et al.
Publicado: (2021)

Prognostic value of primary tumor surgery in de novo stage IV breast cancer patients with different metastatic burdens: a propensity score-matched and population-based study
por: Yang, Yun-Song, et al.
Publicado: (2019)

Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer
por: Narita, Shintaro, et al.
Publicado: (2019)

Prognostic value of the nutritional risk index in patients with newly diagnosed multiple myeloma
por: Zhang, Limei, et al.
Publicado: (2022)

Prognostic value of pre-treatment FDG PET/CT SUVmax for metastatic lesions in de novo metastatic nasopharyngeal carcinoma following chemotherapy and locoregional radiotherapy
por: Yan, Wenbin, et al.
Publicado: (2023)

LncRNA PlncRNA-1 accelerates the progression of prostate cancer by regulating PTEN/Akt axis
por: Cui, Zilian, et al.
Publicado: (2021)

Retrospective validation of bone risk stratification criteria for men with de novo metastatic hormone-naive prostate cancer in China
por: Zhang, Yang, et al.
Publicado: (2023)

External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer
por: Yang, Yun-Jie, et al.
Publicado: (2018)

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients
por: Wang, Yue, et al.
Publicado: (2017)

Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma
por: Wang, Xiaoxiao, et al.
Publicado: (2018)

De Novo PTEN Mutation in a Young Boy with Cutaneous Vasculitis
por: Mauro, Angela, et al.
Publicado: (2017)

Novel metastatic burden‐stratified risk model in de novo metastatic hormone‐sensitive prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma
por: Yang, Peiyu, et al.
Publicado: (2022)

Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer
por: Reverberi, C., et al.
Publicado: (2020)

Genomic Rearrangements of PTEN in Prostate Cancer
por: Phin, Sopheap, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_n9eokjtf7b13s9b5na6u3l0vj7